Domperidone: a peripherally acting dopamine2-receptor antagonist.
Identifieur interne : 000021 ( Ncbi/Merge ); précédent : 000020; suivant : 000022Domperidone: a peripherally acting dopamine2-receptor antagonist.
Auteurs : J A Barone [États-Unis]Source :
- The Annals of pharmacotherapy [ 1060-0280 ] ; 1999.
English descriptors
- KwdEn :
- Animals, Data Collection, Diabetes Mellitus (drug therapy), Domperidone (adverse effects), Domperidone (pharmacology), Domperidone (therapeutic use), Dopamine Antagonists (pharmacology), Dopamine Antagonists (therapeutic use), Drug Interactions, Gastrointestinal Diseases (drug therapy), Gastrointestinal Motility (drug effects), Gastroparesis (drug therapy), Humans, Parkinson Disease (drug therapy), Vomiting (drug therapy).
- MESH :
- chemical , adverse effects : Domperidone.
- drug effects : Gastrointestinal Motility.
- drug therapy : Diabetes Mellitus, Gastrointestinal Diseases, Gastroparesis, Parkinson Disease, Vomiting.
- chemical , pharmacology : Domperidone, Dopamine Antagonists.
- chemical , therapeutic use : Domperidone, Dopamine Antagonists.
- Animals, Data Collection, Drug Interactions, Humans.
Abstract
To review the pharmacology, pharmacokinetics, efficacy, and safety of domperidone in the treatment of gastrointestinal motility disorders and emesis.
DOI: 10.1345/aph.18003
PubMed: 10332535
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001715
- to stream PubMed, to step Curation: 001715
- to stream PubMed, to step Checkpoint: 001715
Links to Exploration step
pubmed:10332535Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Domperidone: a peripherally acting dopamine2-receptor antagonist.</title><author><name sortKey="Barone, J A" sort="Barone, J A" uniqKey="Barone J" first="J A" last="Barone">J A Barone</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy Practice and Administration, College of Pharmacy, Rutgers-The State University of New Jersey, Piscataway 08855, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacy Practice and Administration, College of Pharmacy, Rutgers-The State University of New Jersey, Piscataway 08855</wicri:regionArea><wicri:noRegion>Piscataway 08855</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1999">1999</date><idno type="RBID">pubmed:10332535</idno><idno type="pmid">10332535</idno><idno type="doi">10.1345/aph.18003</idno><idno type="wicri:Area/PubMed/Corpus">001715</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001715</idno><idno type="wicri:Area/PubMed/Curation">001715</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001715</idno><idno type="wicri:Area/PubMed/Checkpoint">001715</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001715</idno><idno type="wicri:Area/Ncbi/Merge">000021</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Domperidone: a peripherally acting dopamine2-receptor antagonist.</title><author><name sortKey="Barone, J A" sort="Barone, J A" uniqKey="Barone J" first="J A" last="Barone">J A Barone</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy Practice and Administration, College of Pharmacy, Rutgers-The State University of New Jersey, Piscataway 08855, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacy Practice and Administration, College of Pharmacy, Rutgers-The State University of New Jersey, Piscataway 08855</wicri:regionArea><wicri:noRegion>Piscataway 08855</wicri:noRegion></affiliation></author></analytic><series><title level="j">The Annals of pharmacotherapy</title><idno type="ISSN">1060-0280</idno><imprint><date when="1999" type="published">1999</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Data Collection</term><term>Diabetes Mellitus (drug therapy)</term><term>Domperidone (adverse effects)</term><term>Domperidone (pharmacology)</term><term>Domperidone (therapeutic use)</term><term>Dopamine Antagonists (pharmacology)</term><term>Dopamine Antagonists (therapeutic use)</term><term>Drug Interactions</term><term>Gastrointestinal Diseases (drug therapy)</term><term>Gastrointestinal Motility (drug effects)</term><term>Gastroparesis (drug therapy)</term><term>Humans</term><term>Parkinson Disease (drug therapy)</term><term>Vomiting (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Domperidone</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Gastrointestinal Motility</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetes Mellitus</term><term>Gastrointestinal Diseases</term><term>Gastroparesis</term><term>Parkinson Disease</term><term>Vomiting</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Domperidone</term><term>Dopamine Antagonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Domperidone</term><term>Dopamine Antagonists</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Data Collection</term><term>Drug Interactions</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To review the pharmacology, pharmacokinetics, efficacy, and safety of domperidone in the treatment of gastrointestinal motility disorders and emesis.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10332535</PMID><DateCreated><Year>1999</Year><Month>07</Month><Day>20</Day></DateCreated><DateCompleted><Year>1999</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1060-0280</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>4</Issue><PubDate><Year>1999</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Annals of pharmacotherapy</Title><ISOAbbreviation>Ann Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Domperidone: a peripherally acting dopamine2-receptor antagonist.</ArticleTitle><Pagination><MedlinePgn>429-40</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To review the pharmacology, pharmacokinetics, efficacy, and safety of domperidone in the treatment of gastrointestinal motility disorders and emesis.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">MEDLINE and Excerpta Medica online databases were searched to identify published reports.</AbstractText><AbstractText Label="STUDY SELECTION" NlmCategory="METHODS">Domperidone has been marketed worldwide outside the US since 1978, and extensive clinical data for this drug are available. This review focuses on the clinical experience from controlled studies of domperidone in the treatment of motility disorders, particularly diabetic gastroparesis. Also, case reports are used in summarizing safety. The control comparator groups included placebo or other prokinetic drugs (metoclopramide and cisapride). Controlled clinical trials of domperidone's efficacy and safety as an antiemetic are also briefly examined. Although a variety of domperidone dosage forms have been marketed, data generated from trials using the 10-mg tablet are highlighted because this is the only dosage form available in Canada and is under investigation in the US.</AbstractText><AbstractText Label="DATA EXTRACTION" NlmCategory="METHODS">Because symptoms do not correlate with objective measures of gastrointestinal motility and they are the primary reason that patients with motility disorders seek treatment, the primary outcome extracted from the clinical studies was symptomatic response to treatment. Safety and efficacy between domperidone and placebo, metoclopramide, or cisapride were compared.</AbstractText><AbstractText Label="DATA SYNTHESIS" NlmCategory="RESULTS">Domperidone, a peripheral dopamine2-receptor antagonist, regulates the motility of gastric and small intestinal smooth muscle and has been shown to have some effects on the motor function of the esophagus. It also has antiemetic activity as a result of blockade of dopamine receptors in the chemoreceptor trigger zone. In controlled clinical trials, domperidone provided better relief of symptoms (anorexia, nausea, vomiting, abdominal pain, early satiety, bloating, distension) than placebo in patients with symptoms of diabetic gastropathy; symptomatic improvement was similar with domperidone and metoclopramide or cisapride. Domperidone also provided short-term relief of symptoms in patients with dyspepsia or gastroesophageal reflux, prevented nausea and vomiting associated with emetogenic chemotherapy, and prevented the gastrointestinal and emetic adverse effects of antiparkinsonian drugs. Because very little domperidone crosses the blood-brain barrier, reports of central nervous system adverse effects, such as dystonic reactions, are rare.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Domperidone is a unique gastrokinetic and antiemetic drug. Because of its favorable safety profile, domperidone appears to be an attractive alternative to metoclopramide. In the management of diabetic gastropathy, domperidone's antiemetic activity distinguishes it from cisapride.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barone</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Practice and Administration, College of Pharmacy, Rutgers-The State University of New Jersey, Piscataway 08855, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Pharmacother</MedlineTA><NlmUniqueID>9203131</NlmUniqueID><ISSNLinking>1060-0280</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>5587267Z69</RegistryNumber><NameOfSubstance UI="D004294">Domperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004294" MajorTopicYN="N">Domperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018492" MajorTopicYN="N">Dopamine Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005769" MajorTopicYN="N">Gastrointestinal Motility</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018589" MajorTopicYN="N">Gastroparesis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014839" MajorTopicYN="N">Vomiting</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>154</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>5</Month><Day>20</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>5</Month><Day>20</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10332535</ArticleId><ArticleId IdType="doi">10.1345/aph.18003</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Barone, J A" sort="Barone, J A" uniqKey="Barone J" first="J A" last="Barone">J A Barone</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000021 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000021 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:10332535
|texte= Domperidone: a peripherally acting dopamine2-receptor antagonist.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:10332535" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |